The company's FY19 dollar revenue growth was muted (at mere 2.2% YoY) mainly on the back of demand fulfilment issues. In this respect, the management has restructured its sales team by hiring sales people, market business leaders and aligning incentive structure. Further, the company is now focusing on a verticals led strategy to drive cross sell and up sell opportunities. The company will focus on healthcare & life sciences, BFSI and industrial to drive sales. It would also aim to increase opportunity in reseller business on the IP side. In addition, M&A; and partnerships would...